ALDX
Another day, another biotech headache
Aldeyra Therapeutics is back in the legal spotlight. Faruqi & Faruqi says it’s investigating claims against the company and is reminding investors about a May 29, 2026 deadline to seek lead-plaintiff status in a federal securities class action.
Why investors should care
This isn’t just paperwork with fancy letterhead. The complaint says Aldeyra allegedly overstated the strength of its reproxalap trial results while the data was actually inconsistent — the kind of thing that can turn a promising biotech story into a very expensive reality check.
The FDA part is the real gut punch
The lawsuit points to Aldeyra’s March 17, 2026 disclosure that the FDA issued a Complete Response Letter rejecting the reproxalap NDA for dry eye disease. The agency said the clinical studies didn’t provide enough well-controlled evidence that the drug works, which is a rough way to discover your crown jewel is not, in fact, a crown jewel.
Big picture
For biotech investors, this is the double whammy: regulatory rejection on one side, securities litigation on the other. Even if the case doesn’t become a giant cash sink, it can hang around like a bad playlist and keep sentiment under pressure until the company proves the pipeline can still deliver.